Effect of Agomelatin on Rat Model of Parkinson's Disease
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Dr Behcet Uz Cocuk Hastaliklari Ve Cerrahisi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: Parkinson's disease is one of the most frequently seen neurodegenerative disorders. A definite cure for this disease is not available yet. Agomelatin is the synthetic analog of melatonin hormone that is synthesized in, and released from the pineal gland . Agomelatin shows its antidepressant effects on central nervous system (CNS) by activating melatonin receptors MT1 and MT2 and antagonizing serotonin 5-HT2C receptors stimulated by monoamine transmitters. In this study, we examined the effects of oral agomelatin administration on Parkinson disease-induced experimental rats by using 6-OHDA. Methods: We administered unilateral intrastriatal 6-OHDA to 45 rats weighing 270-330 gr, in three different groups. We applied dissolver on control group; in other two groups we administered agomelatin at daily doses of 5 mg/kg and 20 mg/kg, respectively, for 15 days. At the end of this treatment process, motor coordination and skills were tested with sticky band test, open-field test and cylinder test, whereas, the severity of dopaminergic damage was tested with apomorphine induced rotation test. Results: in our study, we found out that in both doses of agomelatin (5 mg/kg/day and 20 mg/kg/day respectively), prevented progression of experimental Parkinson disease induced with 6-OHDA in rats. Conclusion: Agomelatin protected striatal neurons from destructive effects in experimental Parkinson's Disease model.
Açıklama
Anahtar Kelimeler
Agomelatin, Melatonin, Parkinson's Disease, Antidepressant, Rat
Kaynak
Izmir Dr Behcet Uz Cocuk Hastanesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
9
Sayı
3
